JP2009541209A5 - - Google Patents

Download PDF

Info

Publication number
JP2009541209A5
JP2009541209A5 JP2009507757A JP2009507757A JP2009541209A5 JP 2009541209 A5 JP2009541209 A5 JP 2009541209A5 JP 2009507757 A JP2009507757 A JP 2009507757A JP 2009507757 A JP2009507757 A JP 2009507757A JP 2009541209 A5 JP2009541209 A5 JP 2009541209A5
Authority
JP
Japan
Prior art keywords
compound
compound according
formula
methyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009507757A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009541209A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/009925 external-priority patent/WO2007127196A2/en
Publication of JP2009541209A publication Critical patent/JP2009541209A/ja
Publication of JP2009541209A5 publication Critical patent/JP2009541209A5/ja
Pending legal-status Critical Current

Links

JP2009507757A 2006-04-25 2007-04-24 β2アドレナリン受容体アゴニストおよびムスカリン受容体アンタゴニスト活性を有するジアルキルフェニル化合物 Pending JP2009541209A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79470206P 2006-04-25 2006-04-25
PCT/US2007/009925 WO2007127196A2 (en) 2006-04-25 2007-04-24 DIALKYLPHENYL COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY

Publications (2)

Publication Number Publication Date
JP2009541209A JP2009541209A (ja) 2009-11-26
JP2009541209A5 true JP2009541209A5 (enExample) 2011-05-19

Family

ID=38577470

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009507757A Pending JP2009541209A (ja) 2006-04-25 2007-04-24 β2アドレナリン受容体アゴニストおよびムスカリン受容体アンタゴニスト活性を有するジアルキルフェニル化合物

Country Status (20)

Country Link
US (3) US7524965B2 (enExample)
EP (1) EP2010489B1 (enExample)
JP (1) JP2009541209A (enExample)
KR (1) KR20090005389A (enExample)
CN (1) CN101426764A (enExample)
AR (1) AR060647A1 (enExample)
AU (1) AU2007243481A1 (enExample)
BR (1) BRPI0710767A2 (enExample)
CA (1) CA2650530A1 (enExample)
CO (1) CO6140054A2 (enExample)
ES (1) ES2391584T3 (enExample)
IL (1) IL194334A0 (enExample)
MA (1) MA30556B1 (enExample)
MX (1) MX2008013555A (enExample)
NO (1) NO20084603L (enExample)
PE (1) PE20080094A1 (enExample)
RU (1) RU2008146383A (enExample)
TW (1) TW200811105A (enExample)
WO (1) WO2007127196A2 (enExample)
ZA (1) ZA200808817B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693202B1 (en) * 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
EP1778626A1 (en) * 2004-08-16 2007-05-02 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
TW200811104A (en) * 2006-04-25 2008-03-01 Theravance Inc Crystalline forms of a dimethylphenyl compound
TW200811105A (en) * 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
PL2242759T3 (pl) * 2008-02-06 2013-06-28 Astrazeneca Ab Związki
ES2417339T3 (es) 2009-04-23 2013-08-07 Theravance, Inc. Compuestos de diamina que tienen actividad antagonista del receptor muscarinico y agonista del receptor beta2-adrenergico
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
PL3061821T3 (pl) 2009-07-22 2020-01-31 PureTech Health LLC Kompozycje do leczenia zaburzeń łagodzonych przez aktywację receptora muskarynowego
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
GB201009801D0 (en) 2010-06-11 2010-07-21 Astrazeneca Ab Compounds 950
JP7096441B2 (ja) 2018-09-28 2022-07-05 カルナ セラピューティックス,インコーポレイテッド ムスカリン受容体活性化によって改善される障害を処置するための組成物及び方法
CN114409556B (zh) * 2022-01-28 2024-10-18 兰州康鹏威耳化工有限公司 一种3,4-二取代-2-氨基苯甲醛的制备方法
CN117924216A (zh) * 2024-01-12 2024-04-26 王叔和生物医药(武汉)有限公司 一种1-哌啶丙酸的合成方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7545894A (en) 1993-09-02 1995-03-22 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
EP0747355A4 (en) 1994-02-10 1997-04-09 Yamanouchi Pharma Co Ltd NEW CARBAMATES AND MEDICINAL PRODUCTS CONTAINING THEM
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
US6362371B1 (en) * 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
US6693202B1 (en) 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
DE19921693A1 (de) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
UA73965C2 (en) 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
US7045658B2 (en) * 2001-03-22 2006-05-16 Glaxo Group Limited Formailide derivatives as beta2-adrenoreceptor agonists
US20030018019A1 (en) 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
ES2329586T3 (es) 2003-11-21 2009-11-27 Theravance, Inc. Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino.
EP1723110A1 (en) 2004-03-11 2006-11-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
TWI374883B (en) 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
WO2006023460A2 (en) 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
EP1778626A1 (en) 2004-08-16 2007-05-02 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
TW200811105A (en) 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
TW200811104A (en) * 2006-04-25 2008-03-01 Theravance Inc Crystalline forms of a dimethylphenyl compound

Similar Documents

Publication Publication Date Title
JP2009541209A5 (enExample)
RU2008146383A (ru) ДИАЛКИЛФЕНИЛЬНЫЕ ПРОИЗВОДНЫЕ, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ β2-АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ МУСКАРИНОВЫХ РЕЦЕПТОРОВ
JP2007514662A5 (enExample)
RU2176145C2 (ru) Синергическое лечение паркинсонизма
JP3981357B2 (ja) 第4級アンモニウム化合物および抗ムスカリン剤としてのそれらの使用
CN1615861A (zh) (1s,2s)-1-(4-羟基苯基)-2-(4-羟基-4-苯基哌啶-1-基)-1-丙醇甲磺酸盐三水合物
JP5860895B2 (ja) 5−メチル−1−(ナフタレン−2−イル)−1h−ピラゾール誘導体
JP2008195730A5 (enExample)
JP2005516067A5 (enExample)
JP2002541104A (ja) ピロリジン系ケモカイン受容体活性調節剤
JP2007509103A5 (enExample)
JP2009532417A5 (enExample)
CN1149454A (zh) 采用神经保护剂治疗耳鸣的方法
RU2011110745A (ru) [4-(5-аминометил-2-фторфенил)-пиперидин-1-ил]-[7-фтор-1-(2-метоксиэтил)-4-трифторметокси-1н-индол-3-ил]-метанон как ингибитор триптазы тучных клеток
JP2012229247A (ja) フェニル酢酸化合物
WO2004010942A2 (en) Substituted heterocyclic compounds as modulators of the ccr5 receptor
RU2016104437A (ru) Соединения хинина, способ их получения и их медицинское применение
JP2007514691A5 (enExample)
JP2010505865A5 (enExample)
TWI433838B (zh) 作為趨化因子受體活性調節劑之六氫吡啶衍生物
JP5468543B2 (ja) アセトアミド立体異性体
KR20140041486A (ko) S1p1 수용체 작용제로서의 신규의 피페리디닐 모노카르복실산
JP2603023B2 (ja) 4−アミノ−1−(2−ピリジル)ピペリジン誘導体の利用
CA2667041A1 (en) N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression
CN110612286A (zh) 氰基取代的稠合双环衍生物及其制备方法和用途